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Background: The purpose of this paper is to examine the acceptability, feasibility, reliability and validity of a new
decision quality instrument that assesses the extent to which patients are informed and receive treatments that
match their goals.
Methods: Cross-sectional mail survey of recent breast cancer survivors, providers and healthy controls and a retest
survey of survivors. The decision quality instrument includes knowledge questions and a set of goals, and results in
two scores: a breast cancer surgery knowledge score and a concordance score, which reflects the percentage of
patients who received treatments that match their goals. Hypotheses related to acceptability, feasibility, discriminant
validity, content validity, predictive validity and retest reliability of the survey instrument were examined.
Results: We had responses from 440 eligible patients, 88 providers and 35 healthy controls. The decision quality
instrument was feasible to implement in this study, with low missing data. The knowledge score had good retest
reliability (intraclass correlation coefficient = 0.70) and discriminated between providers and patients (mean
difference 35%, p< 0.001). The majority of providers felt that the knowledge items covered content that was
essential for the decision. Five of the 6 treatment goals met targets for content validity. The five goals had
moderate to strong retest reliability (0.64 to 0.87). The concordance score was 89%, indicating that a majority had
treatments concordant with that predicted by their goals. Patients who had concordant treatment had similar levels
of confidence and regret as those who did not.
Conclusions: The decision quality instrument met the criteria of feasibility, reliability, discriminant and content
validity in this sample. Additional research to examine performance of the instrument in prospective studies and
more diverse populations is needed.Background
The majority of patients diagnosed with early stage
breast cancer are eligible to decide between having a
mastectomy or lumpectomy with radiation (breast con-
serving therapy), yet this decision can be very challen-
ging. Guidelines and consensus statements for breast
cancer treatment emphasize the equivalence of mastec-
tomy and breast conserving therapy for survival [1-3].
However, these options differ on other dimensions that* Correspondence: ksepucha@partners.org
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reproduction in any medium, provided the ormatter to patients, particularly regarding appearance,
need for radiation, likelihood of re-excision and risk of
local recurrence.
After many years of increasing breast conserving sur-
gery rates, several recent studies suggest that mastec-
tomy rates are rising [4,5]. Proposed reasons for the rise
have focused on different factors such as increased use
of MRI imaging, younger patient age and patient prefer-
ence. Rates of breast conserving surgery or rates of
mastectomy have been proposed as quality measures for
breast surgery; however, both of these measures have
been found to be lacking [6,7]. In this situation, where
survival is equivalent, the “best” treatment is dependent
upon how each individual patient weighs the otherl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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rence and concerns about radiation. A measure that
reports on high or low utilization does not provide any
evidence that the right procedure is being used on the
right patient.
For many situations, including surgery for early breast
cancer, the appropriateness of surgery cannot be deter-
mined solely based on clinical factors [8,9]. An inter-
national consensus process including clinicians, patients
and decision making experts endorsed a definition of de-
cision quality that focuses on two key areas: (1) the ex-
tent to which patients are informed and (2) the extent to
which treatments match what is most important to
patients [10]. This definition of decision quality was
taken as the basis for the development of a survey in-
strument to measure patients’ knowledge and the match
between their goals and type of breast cancer surgery
received.
In breast cancer, a few studies have used knowledge
questionnaires to assess how informed breast cancer
patients were about the surgery decision [11-14]. Other
studies have examined patients’ goals and found that
cosmetic concerns and concerns about recurrence play a
big role in patients’ decisions, in addition to fear of radi-
ation and desire to follow the doctors’ recommendation
[15-19]. Each of these studies used different survey
instruments and none of the studies examined both
knowledge and extent to which patients’ goals were
aligned with treatment. In summary, there is a lack of
comprehensive, well validated instruments to measure
the quality of surgical decisions in breast cancer.
To address this gap, a patient-reported survey instru-
ment for early stage invasive breast cancer surgery deci-
sions was developed to assess the extent to which
patients were informed and received treatments that
matched their goals. It is important that patient reported
surveys demonstrate both strong psychometric proper-
ties (e.g., reliability and validity) and clinical sensibility
(e.g., acceptability and feasibility) [20]. In this study, we
examined performance of the Breast Cancer Surgery De-
cision Quality Instrument (BCS-DQI) along these cri-
teria using three study samples: (1) breast cancer
patients who had made a surgical treatment decision
two or three years prior to the survey (2) breast cancer
health care providers and (3) a group of healthy controls
who had never had breast cancer. These samples provide
complementary data on the performance of the instru-
ment. The retrospective patient sample provided an
“experienced” sample to evaluate the items and to exam-
ine stability of the responses. The provider sample was
used to examine content validity and discriminant valid-
ity of the knowledge score. The healthy control sample
was also used to examine discriminant validity of the
knowledge score.Methods
Approach and instrument development
The BCS-DQI has two decision-specific sections: (1) a
set of knowledge questions to determine whether
patients are informed and (2) a set of goals and concerns
that are used in a model to determine the concordance,
or extent to which patients receive treatments that
reflected what is most important to them.
The definition of decision quality used to guide the in-
strument was validated by the International Patient De-
cision Aid Standards group [10]. The approach to
instrument development was based on a conceptual
framework of shared decision making by Mulley [21]
and extended by Sepucha and Mulley [22] and Sepucha
et al [23]. This framework takes a systems view of deci-
sion making and draws from both normative and behav-
ioral decision theories. Both theories assume that people
are goal-directed and will make choices that are in their
best interest. Normative theories have fairly strict
assumptions of pure rationality, whereas our approach
draws from behavioural theories that recognize limita-
tions (cognitive capacity, competing interests, biases and
heuristics) that may result in deviations from rational
choice. In addition, normative theories only consider
utilities for health states as appropriate influences on
choices, we have relaxed this to include other factors
(e.g. the recovery time or number of surgeries) that
may also appropriately influence choices. These factors
are more generally referred to as “goals and concerns.”
The process for developing the BCS-DQI and prelim-
inary validation work has been described in detail else-
where [24,25]. The key content for the items was
derived from the conceptual framework with significant
input from breast cancer survivors and multidisciplinary
group of clinical experts. The content of the knowledge
items and goals was selected to cover core areas, but it
was not meant to be exhaustive. For example, we did
not include all factors that might influence patients’ pre-
ferred treatment, such as spouse’s goals, and instead fo-
cused on how patients felt about key tradeoffs for the
two main options. Experts in survey research drafted
multiple choice and open-ended items that covered the
content. The draft surveys were subjected to cognitive
testing with breast cancer survivors (n = 6), during which
respondents completed the instrument while talking out
loud to explain their thinking and interpretation of the
instructions, items, and responses. Based on those
results, minor revisions were made to improve accept-
ability and comprehension of the instruments.
Sample and procedures
Adult women patients diagnosed in 2005 or 2006 with
early stage (Stage 1 or 2) breast cancer were identified
through cancer registries at four participating sites.
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breast cancer, prior radiation) were set to ensure that the
majority of patients were clinically eligible for both mast-
ectomy and lumpectomy. Each patient’s treating phys-
ician had to approve contact. All patients received the
study packet in the mail, and non-respondents received a
reminder phone call after two weeks and a reminder
packet after four weeks. Respondents received a small in-
centive with the initial packet and a small compensation
(e.g., book of stamps) for completing the survey. A subset
of patient respondents across all sites was sent a second,
identical survey by mail approximately four weeks after
responding, to assess test-retest reliability.
All health care professionals (surgeons, radiation
oncologists, medical oncologists, plastic surgeons and
oncology nurses) who work with breast cancer patients
at the participating sites were invited to complete the
knowledge portion of the decision quality instruments.
Providers received the survey by mail. Non-responders
received an email reminder after two weeks and a re-
minder mailing after four weeks. Provider respondents
received $50 cash or a gift card upon completion of the
survey.
Healthy controls who did not have a history of breast
cancer or a first degree relative (mother, sister or daugh-
ter) with breast cancer and who were not health care
providers, were recruited through email bulletins sent to
all employees at one of the sites. Women were screened
by phone and eligible women were mailed the surveys.
Non-respondents received a reminder phone call after
two weeks and a reminder mailing after four weeks.
Respondents received $10 for completing the survey.
The study was approved by and conducted in accord-
ance with the policies set out by the participating sites’
Institutional Review Boards.
Measures
Data on treatment stage was taken from the cancer
registry.
Patient survey
Patients reported standard demographics and breast
cancer treatments.
Breast Cancer Surgery Decision Quality Instrument
(BCS-DQI): included two main parts (1) 13 multiple
choice and 2 open-ended knowledge items and (2) 8
goals and concerns rated on an 11-point scale from 0
(not at all important) to 10 (extremely important).
Other items were included in the patient survey to as-
sess the following aspects of the decision:
Top three goals and concerns: patients selected their
top three goals and concerns from those included in
the BCS-DQI.Patients preferred treatment: a single item asked,
“Which treatment was your personal preference?” with
possible responses of Mastectomy, Lumpectomy and
Radiation or I am not sure.
Treatment received: was defined as the final surgical
treatment received.
Decision confidence: assessed with one item, “On a
scale of 0 to 10 where 0 is not at all confident and 10 is
extremely confident, how confident are you that the
decision about breast surgery was the right one for
you?”
Decision regret: assessed with one item, “If you had the
chance to make the decision again, would you have the
same type of surgery? Definitely yes, probably yes, not
sure, probably no, definitely no”.
Provider survey
Providers completed the knowledge portion of the BCS-
DQI, and indicated the importance of each knowledge item
on a scale of 1 (not important) to 4 (essential) and how
well the overall set of items covered the essential informa-
tion on a scale of 1 (not at all well) to 4 (extremely well).
Healthy control survey
Participants completed the knowledge portion of the
BCS-DQI and some demographic items.
Analysis
Sample evaluation
First, the sample characteristics were compiled to see
how well they matched the sampling plan. Two-sample
t-tests and chi-square tests were used to compare the
patient characteristics between responders and non-
responders. Chi-square tests were used to compare the
response rate among sites. We also examined the inter-
action between patient characteristics and response rate
by site. Additionally, two-sample t-tests and chi-square
tests were used to compare demographics between
patients and healthy volunteers. Next, the item non-
response was examined.
Item retention and deletion
Items were examined for issues such as difficulty (e.g.
knowledge items that were too easy, where healthy
volunteers scored >80% or too hard, where provider
average scores <50%), problematic format (if >5% had
problems such as two responses check off when only
one was expected), redundancy (items that had very high
>0.8 inter-item correlation), and floor or ceiling effects
(scores at top or bottom of the range for knowledge
scores or goals). [26,27] The data were discussed by a
steering group of six people that included experts in sur-
vey research, decision sciences and clinical experts in
Sepucha et al. BMC Medical Informatics and Decision Making 2012, 12:51 Page 4 of 10
http://www.biomedcentral.com/1472-6947/12/51breast cancer (including three of the authors KS, CL,
CC). Problematic items were deleted or revised.
BCS-DQI knowledge score
Each item received one point for correct response. A
mean knowledge score was standardized by dividing the
number of correct responses by the number of items,
resulting in scores ranging from 0% to 100%. Open-
ended items were scored correct if they fell within a
range that was pre-determined by medical experts based
on clinical evidence. Items with multiple parts were
weighted to sum to one. The response, “I am not sure,”
was considered incorrect. We scored missing responses
as 1/k where k was the number of possible responses to
the item (essentially equivalent to guessing). A know-
ledge score was calculated for every respondent who
completed at least 50% of the items.
BCS-DQI concordance score
There is no standard approach to measuring concord-
ance between patients’ goals and treatments [28]. The ap-
proach follows that used by Barry et al (1995) to examine
the extent to which patients’ goals are associated with
treatments [29]. We examined whether having mastec-
tomy was associated with stage of disease and each of the
goals both in univariate analyses, using t-tests for con-
tinuous variables and Chi-squared tests for categorical
variables, and in multivariable analysis using a logistic re-
gression model with treatment (mastectomy vs. lumpec-
tomy) as the dependent variable. For the regression
model, the missing responses from the goal items were
imputed from the other available goal items using the
EM algorithm [30].
We used the regression model to determine the model
predicted probability of mastectomy for each patient.
Patients with a predicted probability ≥0.5 who had mastec-
tomy and those with a predicted probability <0.5 who had
lumpectomy, were classified as concordant. A summary
concordance score was calculated that indicated the per-
centage of patients whose decisions “matched” their goals.
The score reflects how well the model fits the observed
data. The interpretation of the score is at the group level.
Groups with higher scores are better at matching treat-
ments to patients’ goals. Patients who had lumpectomy fol-
lowed by mastectomy were excluded from the concordance
model as they were not clinically eligible for both options.
Clinical considerations (e.g. inability to get clear margins)
appropriately guided treatment for these patients, as a re-
sult, these patients might look like their goals are mis-
matched from their final treatment, mastectomy.
BCS-DQI screener
A short version of the DQI that includes 5 of the know-
ledge items and 4 of the goals was also created andscored in comparable way to the longer version. All of
the goals that were significant in the multivariate con-
cordance model are included in the screener version as
well as concerns about reducing chance of having cancer
come back in the breast.
Acceptability and feasibility
Acceptability was examined using length of time to
complete the instrument, which was self-reported by
patients, and response rates. Feasibility was examined
using rates of missing data, with any item with more
than 5% missing responses considered problematic and
subject to revision. We examined association between
average time to complete and missing responses by edu-
cation level using ANOVA.
Assessment of reliability
Reproducibility, or test-retest reliability, for the full
knowledge score and the screener knowledge scores and
the individual goals was calculated using intraclass cor-
relation coefficient (ICC). The a priori target was to ex-
ceed 0.7. [27] The knowledge items do not draw from a
single underlying construct; as a result, we do not report
Cronbach’s alpha or internal consistency.
Assessment of validity
There is no gold standard for knowledge score, goals and
concerns, or concordance score. We tested several hy-
potheses, developed a priori, to provide evidence of
validity:
(1)Content validity hypotheses:a. For knowledge: More than 70% of providers will
report that the knowledge items covered the key
content very or extremely well.
b. For goals and concerns: At least 20% of patients
will include the item as one of their top three
issues for the decision.
(2)Discriminant validity hypotheses:
a. Providers would be more knowledgeable than
patients, who in turn would be more
knowledgeable than the healthy controls (tested
using analysis of variance (ANOVA) with planned
comparisons). This was tested for the full version
and the screener version.
b. The individual goals and concerns will
discriminate significantly between those who have
mastectomy and those who have lumpectomy
(tested using one-sided t-tests). For example,
patients who rate the importance of “avoiding
radiation” highly should be more likely to have
Table 1 Demographic and treatment characteristics of
patient and healthy control samples
Patients Healthy controls
Characteristic N= 440 N=35
Age in years, mean (SD) 56.9 (11.3) 42.4 (10.9)
Race, N (%)
White 365 (83.0) 26 (74.3)
Black 35 (8.0) 3 (8.6)
Other 40 (9.1) 5 (14.3)
Education, N (%)
High school or less 55 (12.5) 0 0
Some college 106 (24.1) 8 (22.9)
College graduate or more 279 (63.4) 27 (77.1)
Annual income, N (%)
<30,000 59 (13.4) 1 (2.9)
30,000-59,999 87 (19.8) 11 (31.4)
60,000-100,000 107 (24.3) 14 (40.0)
>100,000 160 (36.4) 8 (22.9)
Marital status, N (%)
Married/Partnered 297 (67.5) 23 (65.7)
Other 141 (32.0) 12 (34.3)
Months since diagnosis, mean (SD) 30.8 (9.8) –
Stage I (vs. II), N (%) 265 (60.2) –
Treatment, N (%)
Mastectomy* (vs. Lumpectomy) 168 (38.2) –
Breast reconstruction 80 (18.2) –
Radiation 256 (58.2) –
*57 patients had lumpectomy initially, followed by mastectomy.
SD=standard deviation.
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highest chance of avoiding radiation).
c. Patients who stated a preference for mastectomy
will have higher model predicted probabilities
than those who were unsure, who in turn will
have higher predicted probabilities than those
who had a preference for lumpectomy and
radiation (tested using ANOVA with planned
comparisons).
(3)Predictive validity for concordance score.
a. Patients who received treatment that matched
that predicted by the regression model will have
higher confidence and less regret than those who
did not (tested using two sided t-test and Chi-
square test).
Results
Response rates and sample
The overall patient response rate was 60%. The eligible
patient sample is described in Table 1. Responders only
differed from non-responders on two factors, race/ethni-
city and site. Responders were more likely to be white
than non-responders (85% vs. 71%, p< 0.001). Response
rates also varied significantly by site (ranged from 49% to
70%, p< 0.001). We examined respondent characteristics
by site, and only one site had signficant interactions. At
that site, non-white race (37% vs. 61%, p = 0.001) and
having hormonal therapy (39% vs. 57% for those who did
and did not have hormonal therapy respectively, p = 0.02)
were associated with a lower response rate.
A majority of providers, 88/116 (79%), completed the
survey. The provider sample was on average 45 years old
(SD 9), mostly female (65%), and in practice for 15 years
(SD 11). The provider sample was 33% medical oncolo-
gists, 30% nurses (including oncology nurses, nurse
practitioners, and registered nurses), 17% general sur-
geons and surgical oncologists, 8% radiation oncologists
and 8% plastic surgeons. The response rate for the
healthy controls was 100%. Healthy controls were sig-
nificantly younger than the patient sample (mean age 42
versus 57, p< 0.001) but did not vary significantly from
the patient sample on any other demographic variables.
Item retention and deletion
The total knowledge scores ranged from 0-100% and
there was no evidence of a floor or ceiling effect, i.e.
scores were not concentrated at the bottom or top of
the scale (see Figure 1). Two knowledge items were
deleted for being too easy and one was deleted for nega-
tive item to total correlation. The reduced set of items
was used in the remaining analyses. For each goal and
concern, the responses spanned the entire range ofpossibilities (0 to 10). One item, “avoid cancer coming
back in the breast,” had evidence of a ceiling effect as
88% of respondents marked 10. All of the goals were
used in the analyses.
Acceptability and feasibility
The BCS-DQI took an average of 6 minutes for patients
to complete (range 1.4-19.0 minutes). The time to
complete was associated with education level, as patients
with high school degree or less took longer than those
with some college and those with college degree or more
(6.8 vs. 6.4 vs. 5.3 minutes respectively, p< 0.001). The
knowledge items had an average of 1.4% missing
responses (range 0.2-2.5%). Four respondents (0.9%) did
not complete enough of the knowledge items to calcu-
late a total knowledge score. The goals and concerns
had a median of 3.3% missing responses (range 0.9-
10.9%). One goal was an outlier for missing responses,
“remove breast for peace of mind,” with 10.9% missing.
The majority of those who skipped it (94%) had had a
Total knowledge score (%)
Fr
eq
ue
nc
y
Figure 1 Knowledge score distributions for patients, providers and healthy controls.
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associated with education level (p = 0.62).Reliability
The retest reliability of the knowledge score was intra-
class correlation coefficient (ICC) = 0.70. The short
(5-item) version of the knowledge score had lower reli-
ability (ICC= 0.60). The retest reliability of the goals
were: keep breast ICC= 0.87, remove breast ICC=0.83,
avoid radiation ICC=0.76, avoid cancer coming back in
the breast ICC=0.66, avoid serious side effects of radi-
ation ICC=0.64, and avoid hassle of radiation ICC=0.61.Validity of knowledge scores
The majority of providers (76.1%) felt that the set of
items covered the key facts very or extremely well sup-
porting content validity.Patients’ mean total knowledge score was 52.7% (SD
21.8). Providers were significantly more informed than
patients (87.7% vs. 52.7%, p< 0.001). Patients were more
informed than healthy controls, but the difference was
not significant (52.7% vs. 49.3%, p = 0.28). Figure 1 shows
the overall distributions and Table 2 shows responses for
selected knowledge items.
The screener knowledge score (5-item) version was
highly correlated with the total knowledge score (Pear-
son =0.80). It also had similar results with providers
being significantly more informed than patients (93.6%
vs. 60.7%, p< 0.001) and with patients having similar
knowledge to the healthy controls (60.7% vs. 57.7%,
p< 0.001).
Validity of concordance score
Only one goal, avoiding the hassle of radiation did not
meet the a priori cutoff of 20% for content validity (19%
Table 2 Responses to selected knowledge items from the Breast Cancer Surgery Decision Quality Instrument
Patients
N (%)
Healthy
Volunteers
N (%)
Providers
N (%)
For most women with early breast cancer, how much would waiting
4 weeks to make a treatment decision affect their chances of survival?
A lot 57 (13) 4 (11) 1 (1)
Somewhat 62 (14) 16 (46) 1 (1)
A little or not at all* 263 (60) 13 (37) 85 (97)
Not sure 55 (13) 2 (6) 1 (1)
With treatment, about how many women diagnosed with early
breast cancer will eventually die of breast cancer?
Most will die of breast cancer 4 (1) 0 0
About half will die of breast cancer 16 (4) 9 (26) 1 (1)
Most will die of something else* 312 (71) 24 (69) 87 (99)
Not sure 106 (24) 2 (6) 0
After which treatment is it more likely that women will need
to have another operation to remove the tumor?
Lumpectomy* 304 (70) 30 (86) 88 (100)
Mastectomy 3 (1) 0 0
Equally likely for both 47 (11) 4 (11) 0
Not sure 78 (18) 1 (3) 0
On average, which women with early breast cancer live longer?
Women who have a mastectomy 42 (10) 9 (26) 3 (3)
Women who have a
lumpectomy and radiation
17 (4) 2 (6) 1 (1)
There is no difference* 245 (57) 11 (31) 84 (96)
Not sure 129 (30) 13 (37) 0
On average, which women have a higher chance of having
cancer come back in the breast that has been treated?
Women who have a mastectomy 1 (0.2) 0 0
Women who have a lumpectomy and radiation* 202 (46) 23 (68) 67 (77)
There is no difference 124 (28.5) 4 (12) 19 (22)
Not sure 108 (25) 7 (21) 1 (1)
*Indicates the correct answer.
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selected it in their top three). All other goals had 30% or
more patients select it as one of their top three issues.
In univariate analyses, five of the six goals significantly
discriminated between the surgical options in the
expected direction. In the multivariable logistic regres-
sion model, three goals were significantly associated with
receipt of mastectomy: desire to keep breast, remove
breast for peace of mind, and avoid radiation (see
Table 3). The logistic regression model had a c statistic
of 0.95, indicating very good predictive accuracy of the
model. The concordance score, or percentage of patients
who got the treatment predicted by the model, was 89%.
Concordance did vary by treatment, as 82% of mastec-
tomy patients were predicted correctly, compared to
93% of lumpectomy patients (p = 0.007).The model discriminated well among patients who sta-
ted a preference for mastectomy, those who were un-
sure, and those who preferred lumpectomy (model
predicted probabilities of 0.70 vs. 0.30 vs. 0.08, respect-
ively, p< 0.0001 for all comparisons). Patients who
“matched” had similarly high levels of confidence in
their decision (9.12 vs. 9.07, p = 0.86) and were just as
likely to want to do the same thing again (91% vs. 85%,
p = 0.13) compared to those who did not match.
Discussion
The purpose of the Breast Cancer Surgery Decision
Quality Instrument is to provide a comprehensive as-
sessment of the extent to which patients make informed
decision and receive treatments that match their goals.
The knowledge score had good retest reliability and was
Table 3 Univariate (t-test or chi-square) and multivariable logistic regression analyses predictors of having
mastectomy
Mast Lump Univariate Multivariable
Factor N=111 N=272 p OR (95% CI)
Stage II (vs. I) 53.2 32.7 0.0002 1.81(0.89, 3.68)
Importance: (on a scale from 0 to 10)
Keep breast 3.0 6.6 <0.0001 0.79 (0.70, 0.88)
Remove breast for peace of mind 9.3 3.5 <0.0001 1.88 (1.60, 2.22)
Avoid having cancer come back in the breast 9.9 9.6 0.0003
Avoid radiation 5.1 2.1 <0.0001 1.23 (1.11, 1.36)
Avoid side effects of radiation 6.0 5.5 0.21
Avoid hassle of radiation 4.4 2.4 <0.0001
Factors in bold were significant in the multivariable regression model and used to calculate the concordance score.
Mast=mastectomy; Lump=lumpectomy; OR=odds ratio; CI=confidence interval.
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concordance score provides an assessment of how well
treatments matched patients’ goals. The goals used in
calculating the concordance score had good retest reli-
ability. Patients were able to complete the BCS-DQI on
their own, with low rates of missing items indicating that
it was feasible.
The knowledge items cover content that the majority
of providers feel is very important for patients to know
before making a decision. Patients had some gaps in
knowledge, e.g. only 57% correctly answering that sur-
vival is the same for mastectomy and lumpectomy with
radiation. It was surprising that the knowledge scores of
the healthy controls were similar to those of the breast
cancer survivors. This result could be due to the fact
that the controls were more knowledgeable generally
(due to working in health care environment), or that
survivors’ breast cancer knowledge had decreased over
time. Other studies have found similarly low levels of
knowledge for patients surveyed much closer to the time
of diagnosis, which suggests that timing may not fully
explain the lack of knowledge for this sample [14,24].
Three of the goals and concerns, importance of keep-
ing the breast, removing the breast for peace of mind,
and avoiding radiation, met the criteria for retest reli-
ability and also discriminated between the options. The
first two goals may appear to be simply two ends of the
same issue, and although they are negatively correlated,
they are not redundant (Pearson =−0.46). Similar con-
cerns have been found to be related to treatment choices
in other breast cancer studies [16,17,19,31]. Clinicians
seeking to elicit patients’ preferences should, at a mini-
mum, discuss how patients feel about keeping or losing
their breast and how they feel about radiation.
The concordance score was high, indicating that most
patients received treatments that matched their goals.
Patients who preferred mastectomy were somewhat less
likely to receive it (82%) compared to those whopreferred lumpectomy (92%). Contrary to our hypoth-
eses, we did not find evidence that respondents who
received treatments that matched their goals had higher
confidence or less decisional regret. This was possibly
due to a ceiling effect with these items, as all patients had
very high confidence and low regret. Several studies have
found a positive relationship between decision making
processes, such as being offered a choice of breast sur-
gery and matching preferred level of involvement in deci-
sion making, with health outcomes including body
image, psychological adjustment, and satisfaction
[18,19,32,33]. It will be important to examine associated
between concordance and these other outcomes in pro-
spective studies.
The definition for concordance used here requires that
the treatments received match patients’ goals. There are
a growing number of studies that are reporting this
metric, although the studies define and measure con-
cordance differently [28]. The multidimensional measure
of informed choice is one approach that combines
knowledge and value concordance into a single measure
[34]. It was developed to measure the quality of decision
about prenatal testing and has been adapted for use in
genetic testing for cancer [34-36]. The ability to reliably
document that the treatments received, or the care
delivered, reflects patients’ goals, needs and wants will
be important.
The BCS-DQI was designed to audit the quality of
decisions and to compare performance of providers or
breast cancer centers on how well they inform their
patients and how well they tailor treatments to patients’
goals. Clinicians have requested a short version that
could be used in routine practice as a screening tool to
assess patients’ knowledge and goals before the visit so
that they could address any gaps. A short version, the
BCS-DQI Screener, includes 5 knowledge items and 5
goals. Since there are fewer items, it might miss know-
ledge gaps or key goals that patients have. The purpose
Sepucha et al. BMC Medical Informatics and Decision Making 2012, 12:51 Page 9 of 10
http://www.biomedcentral.com/1472-6947/12/51is to stimulate conversation between patients and provi-
ders about options, outcomes and goals, but not to limit
content to only those items included.
Collins et al. (2009) surveyed newly diagnosed patients
with an earlier version of the BCS-DQI Screener after
patients had viewed a decision aid and before they saw
their surgeon. They found high patient knowledge
scores, for example, 98% of respondents answered the
question about survival equivalence of the treatments
correctly compared to 57% from the retrospective sam-
ple reported here [37]. In general, the patients’ know-
ledge scores in their study (86%) were comparable to the
providers’ scores (87%). Further, in the Collins study, the
same three goals were significant in the multivariable
treatment model, suggesting the concordance model
may hold for newly diagnosed patients who are actively
making the treatment decision [37].
The current study has several limitations that should
be noted. First, it was a retrospective study and
patients were surveyed about 2 ½ years after the deci-
sion during which time their knowledge, goals and
concerns likely changed. The survey relies on patient
report and may not fully reflect what information was
conveyed by clinicians during the decision making
process. The sample was from four academic, National
Cancer Institute-designated comprehensive cancer cen-
ters, and the performance may be different in commu-
nity settings. Non-white patients had a lower response
rate than white patients which raise questions about
acceptability across diverse populations. Several studies
have documented lower response rates and lower par-
ticipation in research studies for non-white participants
[38,39]. Further, the content validity was established on
the full set of items and it is possible that the reduced
set and the 5-item screener would not be reviewed
as highly. It will be important to further test the
BCS-DQI in order to understand the acceptability and
performance of the instrument across more diverse
populations and practice settings, and with patients at
the time of the decision.Conclusions
The pressure on hospitals and health care providers to
justify surgical treatments will continue to mount. Hav-
ing a well validated, feasible survey instrument that can
provide evidence that patients were informed and that
the treatment reflected patients’ goals will be an import-
ant part of efforts to document quality of breast care.
The BCS-DQI met several key criteria for high quality,
patient-reported survey instruments including feasibility,
retest reliability, discriminant validity and content valid-
ity, and may be useful in assessing the quality of breast
cancer surgical decisions.Competing interests
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